

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2022 September 14; 28(34): 4929-5092



### REVIEW

- 4929** Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma  
*Sposito C, Citterio D, Viridis M, Battiston C, Droz Dit Busset M, Flores M, Mazzaferro V*

### MINIREVIEWS

- 4943** Diagnosis, treatment, and current concepts in the endoscopic management of gastroenteropancreatic neuroendocrine neoplasms  
*Iabichino G, Di Leo M, Arena M, Rubis Passoni GG, Morandi E, Turpini F, Viaggi P, Luigiano C, De Luca L*
- 4959** Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy  
*Iizuka M, Etou T, Sagara S*

### ORIGINAL ARTICLE

#### Basic Study

- 4973** Long noncoding RNA ZNF1-AS1 promotes the invasion and proliferation of gastric cancer cells by regulating LIN28 and CAPRIN1  
*Zhuo ZL, Xian HP, Sun YJ, Long Y, Liu C, Liang B, Zhao XT*
- 4993** Oxidized low-density lipoprotein stimulates CD206 positive macrophages upregulating CD44 and CD133 expression in colorectal cancer with high-fat diet  
*Zheng SM, Chen H, Sha WH, Chen XF, Yin JB, Zhu XB, Zheng ZW, Ma J*
- 5007** Ji-Chuan decoction ameliorates slow transit constipation *via* regulation of intestinal glial cell apoptosis  
*Wang XM, Lv LX, Qin YS, Zhang YZ, Yang N, Wu S, Xia XW, Yang H, Xu H, Liu Y, Ding WJ*

#### Retrospective Cohort Study

- 5023** Pregnancy and fetal outcomes of chronic hepatitis C mothers with viremia in China  
*Pan CQ, Zhu BS, Xu JP, Li JX, Sun LJ, Tian HX, Zhang XH, Li SW, Dai EH*

#### Retrospective Study

- 5036** Trends in hospitalization for alcoholic hepatitis from 2011 to 2017: A USA nationwide study  
*Wakil A, Mohamed M, Tafesh Z, Niazi M, Olivo R, Xia W, Greenberg P, Pyrsopoulos N*
- 5047** Analysis of invasiveness and tumor-associated macrophages infiltration in solid pseudopapillary tumors of pancreas  
*Yang J, Tan CL, Long D, Liang Y, Zhou L, Liu XB, Chen YH*

**Observational Study**

- 5058** Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study

*Bessissow T, Nguyen GC, Tarabain O, Peyrin-Biroulet L, Foucault N, McHugh K, Ruel J*

**CASE REPORT**

- 5076** Gastrointestinal tumors in transplantation: Two case reports and review of literature

*Stammler R, Anglicheau D, Landi B, Meatchi T, Ragot E, Thervet E, Lazareth H*

- 5086** Spontaneous expulsion of a duodenal lipoma after endoscopic biopsy: A case report

*Chen ZH, Lv LH, Pan WS, Zhu YM*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastroenterology*, Abhinav Vasudevan, BMed, MPH, FRACP, PhD, Staff Physician and Medical Lead in Inflammatory Bowel Diseases, Department of Gastroenterology and Hepatology, Eastern Health, Box Hill 3128, Australia

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

**INDEXING/ABSTRACTING**

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Hua-Ge Yu; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ru Fan.

**NAME OF JOURNAL**

*World Journal of Gastroenterology*

**ISSN**

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

**LAUNCH DATE**

October 1, 1995

**FREQUENCY**

Weekly

**EDITORS-IN-CHIEF**

Andrzej S Tarnawski

**EDITORIAL BOARD MEMBERS**

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

**PUBLICATION DATE**

September 14, 2022

**COPYRIGHT**

© 2022 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Efficacy of cytappheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy

Masahiro Iizuka, Takeshi Etou, Shiho Sagara

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): C, C, C  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Ali SNH, Jordan; Li HY, China; Sitkin S, Russia; Wen XL, China

**Received:** May 30, 2022

**Peer-review started:** May 30, 2022

**First decision:** June 18, 2022

**Revised:** July 16, 2022

**Accepted:** August 16, 2022

**Article in press:** August 16, 2022

**Published online:** September 14, 2022



**Masahiro Iizuka, Shiho Sagara,** Akita Health Care Center, Akita Red Cross Hospital, Akita 010-0001, Japan

**Masahiro Iizuka, Takeshi Etou,** Department of Gastroenterology, Akita Red Cross Hospital, Akita 010-1495, Japan

**Corresponding author:** Masahiro Iizuka, MD, PhD, Director, Doctor, Akita Health Care Center, Akita Red Cross Hospital, 3-4-23 Nakadori, Akita 010-0001, Japan.  
[maiizuka@woody.ocn.ne.jp](mailto:maiizuka@woody.ocn.ne.jp)

### Abstract

For the optimal management of refractory ulcerative colitis (UC), secondary loss of response (LOR) and primary non-response to biologics is a critical issue. This article aimed to summarize the current literature on the use of cytappheresis (CAP) in patients with UC showing a poor response or LOR to biologics and discuss its advantages and limitations. Further, we summarized the efficacy of CAP in patients with UC showing insufficient response to thiopurines or immunomodulators (IM). Eight studies evaluated the efficacy of CAP in patients with UC with inadequate responses to thiopurines or IM. There were no significant differences in the rate of remission and steroid-free remission between patients exposed or not exposed to thiopurines or IM. Three studies evaluated the efficacy of CAP in patients with UC showing an insufficient response to biologic therapies. Mean remission rates of biologics exposed or unexposed patients were 29.4 % and 44.2%, respectively. Fourteen studies evaluated the efficacy of CAP in combination with biologics in patients with inflammatory bowel disease showing a poor response or LOR to biologics. The rates of remission/response and steroid-free remission in patients with UC ranged 32%-69% (mean: 48.0%, median: 42.9%) and 9%-75% (mean: 40.7%, median: 38%), respectively. CAP had the same effectiveness for remission induction with or without prior failure on thiopurines or IM but showed little benefit in patients with UC refractory to biologics. Although heterogeneity existed in the efficacy of the combination therapy with CAP and biologics, these combination therapies induced clinical remission/response and steroid-free remission in more than 40% of patients with UC refractory to biologics on average. Given the excellent safety profile of CAP, this combination therapy can be an alternative therapeutic strategy for UC refractory to biologics. Extensive prospective studies are needed to understand the efficacy of combination therapy with CAP and biologics.



**Key Words:** Ulcerative colitis; Inflammatory bowel disease; Cytapheresis; Granulocyte and monocyte adsorptive apheresis; Anti-tumor necrosis factor- $\alpha$  antibody; Combination therapy

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Management of refractory ulcerative colitis (UC) experiencing primary non-response or loss of response to biologics is a critical issue. We first summarized the efficacy of cytapheresis (CAP) for such patients. Although CAP tended to have lower effects for induction of remission in patients with UC who were refractory to biologics, combination therapies with CAP and biologics induced clinical remission or response in more than 40% of such patients with UC on average. Given the excellent safety profile of CAP, we believe that this combination therapy can be an alternative therapeutic strategy for such refractory UC patients.

**Citation:** Iizuka M, Etou T, Sagara S. Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy. *World J Gastroenterol* 2022; 28(34): 4959-4972

**URL:** <https://www.wjgnet.com/1007-9327/full/v28/i34/4959.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v28.i34.4959>

## INTRODUCTION

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) of the colon characterized by a relapsing and remittent course[1,2]. Multiple factors, such as genetic background, environmental and luminal factors, and mucosal immune dysregulation, have been suggested to contribute to UC pathogenesis[1]. Several treatments for UC are available to induce and maintain the clinical remission of the disease. For patients with mild to moderate UC, 5-aminosalicylic acid (5-ASA) is generally used, and more than 90% of patients receive 5-ASA within 1 year of diagnosis[3]. Corticosteroids (CSs) are the first-line treatment to induce remission in moderate to severe UC[2]. It was reported that immediate outcomes from CSs were complete remission in 54%, partial remission in 30%, and no response in 16% of patients[4]. Despite the effectiveness of CSs in patients with UC, it has been reported that the rate of steroid dependence was 17%-22% at 1 year following treatment with the initial CS therapy and increased to 38% mostly within 2 years[4-8].

Thiopurines have been conventionally used for the treatment of steroid-dependent UC[9-14]. The rates of the induction of CS-free remission with thiopurines in steroid-dependent patients with UC were reported to be 44% and 53%, respectively[13,14]. However, it has also been reported that thiopurine therapy has failed in approximately 25% of IBD patients within 3 mo after treatment initiation, mostly due to drug intolerance or toxicity[11].

Along with the recent advancements in the treatment for UC, effective treatments, including biologics [anti-tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) antibodies[15-25], anti-integrin monoclonal antibody[26]], Janus kinase (JAK) inhibitor[27] and tacrolimus[28,29], have been developed for refractory UC. A meta-analysis showed that anti-TNF- $\alpha$  antibodies had more clinical benefits than placebo as evidenced by the former's increased frequency of clinical, steroid-free, and endoscopic remission and decreased frequency of colectomy[30]. It has been reported that the rates of induction of steroid-free remission in refractory patients with UC with anti-TNF- $\alpha$  antibodies ranged from 40.0%-76.5% [2,16,18,21,22,24]. Vedolizumab (VDZ) is an anti-integrin monoclonal antibody. Studies on VDZ showed that clinical response and remission were achieved in 51% and 30% of patients with UC by week 14, respectively [31]. However, despite the significant efficacy of biologics for UC, secondary loss of response (LOR) is a common clinical problem. It was reported that the rate of LOR to anti-TNF- $\alpha$  antibodies in UC ranged from 23%-46% at 12 mo after anti-TNF- $\alpha$  initiation[32]. It was also reported that the incidence rates of LOR to adalimumab (ADA) and infliximab (IFX) were 58.3% and 59.1% during maintenance therapy, respectively (mean follow-up: 139 and 158.8 wk, respectively)[33]. Recent data from a systematic review showed that the pooled incidence rates of LOR to VDZ were 47.9 and 39.8 per 100 person-years of follow-up among patients with Crohn's disease (CD) and UC, respectively[34]. Considering these results, secondary LOR as well as primary non-response to biologics, are a critical issue for the optimal management of refractory UC. In this context, recent studies have shown the efficacy of use of cytapheresis (CAP) in such patients with UC[35-51].

CAP is a non-pharmacological extracorporeal therapy and has been developed as a treatment for UC [52-58]. CAP is performed using two methods, namely, granulocyte and monocyte adsorptive apheresis (GMA), which uses cellulose acetate beads (Adacolumn, JIMRO Co., Ltd., Takasaki, Japan), and leukocytapheresis (LCAP), which uses polyethylene phthalate fibers (Cellsorba, Asahi Kasei Medical Co., Ltd., Tokyo, Japan)[42,52]. GMA selectively depletes elevated levels of granulocytes and monocytes

from the patients' circulation, but spares most of the lymphocytes[52]. LCAP exerts its anti-inflammatory effects by removing activated leukocytes or platelets from the peripheral blood through extracorporeal circulation[42]. It has been reported that CAP is an effective therapeutic strategy for active refractory UC with fewer adverse effects[52-59]. In addition, it is notable that there have been no reports showing LOR to CAP during the treatment.

As described above, recent studies have shown the efficacy of the use of CAP in patients with UC showing a poor response or LOR to biologics, but the results of these studies have not been summarized to date. The purpose of this article is to summarize the current literature on the use of CAP as an alternative therapeutic strategy for patients with UC showing insufficient response or LOR to biologics and discuss the advantages and limitations of this strategy. We also summarized the efficacy of CAP for patients with UC showing insufficient response to thiopurines or immunomodulators (IM)[36,37,42,58-62].

## LITERATURE SEARCH STRATEGY

Electric search for studies published before December 2021 was performed in the PubMed databases. The search terms used were as follows; ulcerative colitis, inflammatory bowel disease, cytappheresis, GMA, biologics, loss of response, anti-TNF- $\alpha$  antibody, infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, combination therapy, thiopurine, and immunomodulator. Reference lists of all relevant articles were searched for further studies. The search was restricted to articles in the English language and included prospective studies, retrospective studies, case series, case reports, and randomized control studies. Subsequently, we generated a state-of-the-art comprehensive review by summarizing the data on the efficacy of CAP in patients with UC (or IBD) showing insufficient or lost response to biologic therapy, and efficacy of CAP in patients with UC showing insufficient response to thiopurines or IM.

## EFFICACY OF CAP IN PATIENTS WITH UC SHOWING INSUFFICIENT RESPONSE TO THIOPURINES OR IM

There were eight studies that evaluated the efficacy of CAP in patients having UC with insufficient response to thiopurines (Table 1)[36,37,42,58-62]. These studies include three prospective studies, two retrospective studies, one historical cohort study, one single-arm, open-label, multicentre trial, and one multicenter cohort study. Among them, four studies showed remission rates, and four studies showed steroid-free remission rates in CAP therapy in patients with UC concomitantly treated with thiopurines or IM. Although the background of the patients in these studies were different, the remission rates in CAP therapy ranged from 40.3%-73% (mean  $\pm$  SD: 56.25  $\pm$  16.03%, median: 55.85%, interquartile range: 41.475%-71.425%) and the steroid-free remission rates in CAP therapy ranged from 36%-56.3% (mean  $\pm$  SD: 47.25  $\pm$  9.99%, median: 48.35%, interquartile range: 37.425%-55.975%) (Figure 1). Among these studies, four[37,42,58,59] compared the rates of clinical remission between the patients exposed to thiopurines or IM and the patients unexposed to them. In all four studies significant differences were not observed in the rates of remission between patients exposed to thiopurines or IM and control. In three of the four studies, the remission rates in patients with UC concomitantly exposed to thiopurines or IM ranged from 45%-73% (mean  $\pm$  SD: 61.57  $\pm$  14.69%, median: 66.7%), and those in patients unexposed to thiopurines or IM ranged from 48%-71% (mean  $\pm$  SD: 62.7  $\pm$  12.8%, median: 69.1%) (Figure 2A).

Specifically, Yokoyama *et al*[42] used LCAP in their study and demonstrated that the clinical remission rate of the patients concomitantly using thiopurines was 73% and that of the patients without using thiopurines was 71%. They showed that in univariate analysis, concomitant use of thiopurine did not show statistically significant differences between the remission and nonremission groups ( $P = 0.623$ ). Yamamoto *et al*[37] used GMA in their study and showed that the clinical remission rate of patients exposed to immunosuppressants was 45%, and that of the patients unexposed to immunosuppressants was 48%. They showed that in the univariate analysis, exposure to immunosuppressants did not affect the likelihood of clinical remission in the treatment of GMA ( $P = 0.61$ ).

Regarding the rate of steroid-free remission, two studies[59,62] compared the rates of steroid-free remission between the patients concomitantly treated with thiopurines or IM and the patients treated without them. These studies showed that significant differences were not observed between the patients concomitantly treated with thiopurines or IM and patients treated without them. The steroid-free remission rates in patients with UC concomitantly treated with thiopurines or IM were 41.7% and 56.3% (mean: 49%) and the rates of steroid-free remission in patients with UC treated without thiopurines or IM were 45.5% and 53.5% (mean: 49.5%), respectively (Figure 2B). Specifically, Ishiguro *et al*[62] showed that in the univariate analysis, IM therapy was not associated with remission induction rate by GMA ( $P = 1.00$ ). However, they also showed that in the multivariate analysis, only IM therapy was associated with an increased risk of relapse (OR: 37.6877, 95% CI: 2.4178-587.4632;  $P = 0.0013$ ).

**Table 1 Efficacy of cytapheeresis in patients with ulcerative colitis showing insufficient response to thiopurine or immunomodulators**

Ref.	Study type	Total number of patients included in the study	Number of patients insufficient response to thiopurine or IM	Regimen of CAP	Rate of remission	Rate of steroid- free remission
Cabriada <i>et al</i> [60], 2010	Prospective study	18 (SD)	18	GMA or LCAP (5-10 sessions, 1 session/wk)		55%
Takayama <i>et al</i> [58], 2013	Historical cohort study	90	14	GMA or LCAP (5-10 sessions, 1-2/wk)	49% (total Pts), pre-use of IM had little effects on the response to therapy	
Yokoyama <i>et al</i> [42], 2014	Prospective Observation Study	623 (for efficacy assessment)	196	LCAP (5-10 sessions, mean 8.4), intensive LCAP was performed in > 70% of Pts	73% (Pts concomitantly treated with thiopurine), 71% (Pts treated without thiopurine), $P = 0.623$	
Imperiali <i>et al</i> [61], 2017	Prospective multicenter study	33 (SD)	33	GMA (5 sessions, 1 session/wk)		36%
Yamamoto <i>et al</i> [37], 2018	Retrospective study	593	159	GMA (5 sessions, 1 to 5 sessions/wk), 5 or 6 GMA were added in Pts who did not achieve clinical remission	45% (Pts exposed to IM), 48% (Pts unexposed to IM), $P = 0.61$	
Dignass <i>et al</i> [36], 2016	Single-arm, open-label, multicentre trial	86 (SD)	83	GMA (5-10 sessions, 1 session/wk)	40.3%	
Ishiguro <i>et al</i> [62], 2020	Multicenter cohort study	102, SD or SR UC Pts were not included	16	GMA (mean number of GMA 9.9 sessions, 1-3 sessions/wk)		56.3% (Pts concomitantly treated with IM), 53.5% (Pts treated without IM), $P = 1.00$
Iizuka <i>et al</i> [59], 2021	Retrospective study	55 (SD: 33, SR: 21)	12	GMA or LCAP [5-20 sessions (mean 8.8), 1-2 sessions/wk (in principle)]	66.7% (Pts concomitantly treated with thiopurine), 69.1% (all Pts), no significant differences	41.7% (Pts concomitantly treated with thiopurine), 45.5% (all Pts), no significant differences

CAP: Cytapheresis; GMA: Granulocyte and monocyte adsorptive apheresis; LCAP: Leukocytapheresis; IM: Immunomodulators (or immunosuppressants); Pts: Patients; SD: Steroid dependent patients; SR: Steroid refractory patients; Intensive LCAP: Defined as performing  $\geq 4$  leukocytapheresis treatment within the first 2 wk.

In summary, it was suggested that CAP has the same effectiveness for induction of remission in patients with UC with and without prior failure to thiopurines or IM.

## EFFICACY OF CAP IN PATIENTS WITH UC SHOWING PREVIOUS BIOLOGICS FAILURE


Three studies have evaluated the efficacy of CAP in patients with UC showing an insufficient response to anti-TNF- $\alpha$  therapy or exposure to biologics compared with biologic naïve patients with UC[35-37] (Table 2). These studies include two retrospective studies and one single-arm open-label multicentre trial. Among these studies, Yamamoto *et al*[37] showed that the clinical remission rate of the patients exposed to biologics was 31%, and that of the patients unexposed to biologics was 48% ( $P = 0.01$ ). They showed that in the univariate analysis, biologic naïve patients responded well to GMA ( $P = 0.01$ ). In multivariate analysis, exposure to biologics was an independent significant factor affecting the clinical efficacy of GMA ( $P = 0.01$ ). Dignass *et al*[36] conducted a study on a large cohort of steroid-dependent patients with UC refractory to immunosuppressant and /or biologic treatment to provide additional clinical data regarding the safety and efficacy of Adacalumn (GMA). They showed that remission was achieved at week 12 in 31/77 [40.3% (95%CI: 29.2, 52.1)] of patients who failed on immunosuppressants, 10/36 [27.8% (95%CI: 14.2, 45.2)] of patients who failed on anti-TNF- $\alpha$  treatment, and 9/30 [30.0% (95%CI: 14.7, 49.4)] of patients who failed on both immunosuppressants and anti-TNF- $\alpha$ treatment. Their results suggested that the remission rate using Adacalumn tended to be lower in patients who failed on anti-TNF- $\alpha$  treatment or on both immunosuppressants and anti-TNF- $\alpha$  treatment compared to that of the patients who failed on immunosuppressants. The remission rates in patients with UC exposed to anti-TNF- $\alpha$  treatment in the two studies were 27.8% and 31% (mean: 29.4%), and the remission rates in



**Table 2 Efficacy of cytopheresis in patients with ulcerative colitis showing previous biologics failure**

Ref.	Study type	Biologics exposure	Number of patients (total number of patients in the study)	Regimen of CAP	Rate of remission	Rate of steroid-free remission
Cabriada <i>et al</i> [35], 2012	Retrospective study (results of nationwide Spanish registry)	IFX	33 (total: 142 SD)	GMA (95% of the Pts), 1-10 sessions (median 5 sessions)		37% (all Pts), no differences in clinical remission were found among those Pts with previous thiopurine or IFX failure
Dignass <i>et al</i> [36], 2016	Single-arm, open-label, multicentre trial	TNF- $\alpha$	37 (total: 86 SD)	GMA (5-10 sessions, 1 session/wk)	27.8% (Pts who failed on TNF- $\alpha$ ), 40.3% (Pts who failed on immunosuppressants)	
Yamamoto <i>et al</i> [37], 2018	Retrospective study	(1) IFX; and (2) ADA	(1) 31; and (2) 36 (total: 593)	GMA (5 sessions, 1 to 5 sessions/wk), 5 or 6 GMA were added in Pts who did not achieve clinical remission	31% (Pts exposed to biologics), 48% (Pts unexposed to biologics), $P = 0.01$	


CAP: Cytopheresis; SD: Steroid dependent patients; GMA: Granulocyte and monocyte adsorptive apheresis; Pts: Patients; IFX: Infliximab; TNF- $\alpha$ : Tumor necrosis factor- $\alpha$ ; ADA: Adalimumab.



**Figure 1** Remission and steroid-free remission rates in cytopheresis therapy in patients with ulcerative colitis concomitantly treated with thiopurines or immunomodulators. Box plot shows that, in cytopheresis therapy, the remission rates range from 40.3%-73% (mean: 56.25%, median: 55.85%, interquartile range: 41.475%-71.425%) and the rates of steroid-free remission range from 36%-56.3% (mean: 47.25%, median: 48.35%, interquartile range: 37.425%-55.975%).

patients with UC unexposed to anti-TNF- $\alpha$  treatment were 40.3% and 48% (mean: 44.15%), respectively (Figure 3).

Cabriada *et al* [35] conducted a clinical study including 142 steroid-dependent patients with UC [previous thiopurines failure 98 (69%), previous IFX failure 33 (23%)] to evaluate the short and long-term effectiveness and safety of leukocytapheresis therapy by means of a nationwide registry of clinical practice. Although the rate of remission in patients who were refractory to thiopurines or IFX was not described in the paper, no differences in clinical remission were found among those with previous thiopurine or IFX failure.



**Figure 2** Remission and steroid-free remission rates in cytapheeresis therapy in patients with ulcerative colitis concomitantly treated with thiopurines or immunomodulators and in those treated without thiopurines or immunomodulators. A: Box plot shows that the rates of remission in patients concomitantly treated with thiopurines or immunomodulators (IM) and in those treated without thiopurines or IM range from 45%-73% (mean: 61.57%, median: 66.7%) and 48%-71% (mean: 62.7%, median: 69.1%), respectively; B: The rates of steroid-free remission in patients with ulcerative colitis (UC) concomitantly treated with thiopurines or IM are 41.7% and 56.3% (mean: 49%), and those in patients with UC treated without thiopurines or IM are 45.5% and 53.5% (mean: 49.5%), respectively.

In summary, it is controversial whether CAP has a similar clinical effect in patients with UC who failed biologics treatment and in biologic naïve patients with UC due to limited studies. However, based on these studies, it is suggested that CAP tended to have less efficacy for induction of clinical remission in patients with UC who failed on anti-TNF- $\alpha$  treatment compared to biologic naïve patients with UC.

## EFFICACY OF COMBINATION THERAPY WITH CAP AND BIOLOGICS IN IBD PATIENTS SHOWING INSUFFICIENT RESPONSE OR LOSS OF RESPONSE TO BIOLOGICS

### *Efficacy of the combination therapy with CAP and biologics*

There have been 14 studies that evaluated the efficacy of the combination therapy of CAP and biologics in IBD patients that were refractory to biologics[38-51] (Table 3). These studies include two prospective studies, four retrospective studies, one preliminary study, and seven case reports. These studies include eight studies evaluating combination therapy with GMA or LCAP and anti-TNF- $\alpha$  (IFX: 6 studies; ADA: 1 study; IFX, ADA, golimumab: 1 study), four studies with GMA and VDZ, one study with GMA and ustekinumab, and one exceptional study with GMA and a pan-JAK inhibitor tofacitinib. Among these 14 studies, seven studies[42,44,45,47-50] examined the efficacy of combination therapies in patients with UC, five studies[38-41,46] examined its efficacy for CD patients, and two studies[43,51] examined its efficacy for both UC and CD patients.


As shown in Table 3, there were differences in the background of the patients and methods of combination therapies among the studies, and heterogeneity existed in the efficacy of the combination therapies with CAP and biologics among the studies. The rates of remission or response to combination therapies in IBD (UC and CD) patients in these studies excluding seven case reports ranged from 32%-100% (mean  $\pm$  SD: 62.72  $\pm$  26.65%, median: 57.85%, interquartile range: 40.175%-89.275%) and the rates of steroid-free remission ranged from 9%-75% (mean  $\pm$  SD: 43  $\pm$  27.4%, median: 44%, interquartile range: 16.25%-68.75%), respectively (Figure 4). Regarding the efficacy of the combination therapies in patients with UC, three studies showed the rates of remission or response, and three studies showed steroid-free remission in the combination therapies of CAP and biologics in patients with UC refractory to biologics. The rates of remission or response ranged from 32%-69% (mean  $\pm$  SD: 47.97  $\pm$  19.0%, median: 42.9%),

**Table 3 Efficacy of combination therapy with cytapheresis and biologics in inflammatory bowel disease patients showing insufficient response or loss of response to biologics**

Ref.	Study type	Biologics to which insufficient response or LOR was shown	Number of patients	Methods of combination therapy	Regimen of CAP	Rate of remission	Rate of response	Rate of steroid-free remission	Rate of AE (%)
González Carro <i>et al</i> [38], 2006	Case report	IFX (LOR)	CD 1	IFX + GMA	GMA 1 session/8 wk, 12 mo	100%			
Fukunaga <i>et al</i> [39], 2010	Case report	IFX (LOR)	CD 1	IFX + GMA	GMA 1 sessions/wk, 3 consecutive weeks × 3 courses and maintenance therapy	100%			0/1 (0%)
Sono <i>et al</i> [40], 2012	Prospective study	IFX (LOR)	CD 15	IFX + GMA	GMA 1 session/wk, 5 consecutive wk		46.7%; a fall in CDAI by more than 15%		
Ozeki <i>et al</i> [41], 2012	Case report	(1) IFX (failure); (2) ADA (failure); (3) Steroid refractory and <i>etc.</i>	(1) CD 1; (2) CD 1; and (3) CD 3	ADA + GMA	GMA 2 sessions/wk, 5 consecutive wk	100%			0/5 (0%)
Yokoyama <i>et al</i> [42], 2014	Prospective observational study	IFX	UC 42	IFX + LCAP	LCAP 5-10 sessions (mean 8.4), intensive LCAP was performed in > 70% of Pts	69.0% (Pts concomitantly treated with IFX)			
Yokoyama <i>et al</i> [43], 2018	Case report	IFX (LOR)	UC 2; CD 1	IFX + GMA	GMA 1 session/wk, 3 consecutive wk or more	UC 100%, CD 100%			
Scrivo <i>et al</i> [44], 2018	Case report	VDZ (primary nonresponse to VDZ; Previous LOR to IFX; Primary non-response to ADA)	UC 1	VDZ + GMA	GMA 1 session/wk, 5 wk			100%	0/1 (0%)
Sáez-González <i>et al</i> [45], 2018	Case report	VDZ (primary nonresponse to VDZ; Primary nonresponse to ADA and IFX)	UC 1	VDZ + GMA	GMA 2 sessions/wk, 5 wk + 14 monthly maintenance sessions			100%	
Tanida <i>et al</i> [46], 2018	Retrospective study	(1) IFX (LOR); (2) ADA (LOR); (3) Steroid refractory	(1) CD 1; (2) CD 1; and (3) CD 1	UST + GMA	GMA: 2 sessions/wk, for 5 consecutive wk	100%		50%	0/3 (0%)
Rodríguez-Lago <i>et al</i> [47], 2019	Retrospective multicenter study	Anti-TNF therapy (IFX 23, ADA 18, GLM 6); Primary nonresponse 49%, LOR 51%	UC 47	Anti-TNF therapy + GMA	GMA 1 sessions/wk 45%, 2 sessions/wk 55%; 5-10 sessions 51%, > 10 sessions 19% (median of 10 sessions)		32%	9%	2/47 (4%)
Rodríguez-Lago <i>et al</i> [48], 2019	Retrospective multicentre pilot study	VDZ (primary nonresponse 25%, secondary LOR 75%); All Pts had previously received anti-TNF agents (IFX 88%, ADA 50%, GLM 38%)	UC 8	VDZ + GMA	GMA: 5-38 sessions (median 15), biweekly 75%, weekly 25%; maintenance GMA 75%, monthly 38%, every 2 wk 25%		Partial Mayo score decreased ( $P = 0.01$ )	38%	0/8 (0%)
Nakamura <i>et al</i> [49], 2020	Case report	VDZ (primary nonresponse to VDZ; Serious	UC 1	VDZ + GMA	semiweekly GMA, 4 wk	100%			

		allergy to IFX)					
Tanida <i>et al</i> [50], 2020	Retrospective study	(1) IFX(LOR); (2) ADA (LOR); (3) Steroid refractory or dependent	(1) UC 2; (2) UC 2; and (3) UC 3	TOF + GMA	GMA: 2 sessions/wk, total 10 sessions	75%	3/7 (43%)
Yokoyama <i>et al</i> [51], 2020	Preliminary study	IFX (LOR)	UC 7; CD 7	IFX + GMA	1 or 2 sessions/wk, for 5 consecutive wk, Pts who did not achieved remission by week 8 underwent another GMA (1 session/wk, 5 consecutive wk)	All IBD 64.3%, UC 42.9%, CD 85.7%	0/14 (0%)

LOR: Loss of response; CAP: Cytapheresis; CD: Crohn's disease; GMA: Granulocyte and monocyte adsorptive apheresis; UC: Ulcerative colitis; LCAP: Leukocytapheresis; AE: Adverse events; IFX: Infliximab; ADA: Adalimumab; Pts: Patients; VED: Vedolizumab; UST: Ustekinumab; TNF- $\alpha$ : Tumor necrosis factor- $\alpha$ ; GLM: Golimumab; TOF: Tofacitinib; Intensive LCAP: Defined as performing  $\geq 4$  leukocytapheresis within the first 2 wk.




DOI: 10.3748/wjg.v28.i34.4959 Copyright ©The Author(s) 2022.

**Figure 3** Remission rates in cytapheeresis therapy in patients with ulcerative colitis exposed to anti-tumor necrosis factor- $\alpha$  treatment and in those unexposed to anti-tumor necrosis factor- $\alpha$  treatment. The remission rates in patients with ulcerative colitis (UC) exposed to anti-tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) treatment are 27.8% and 31% (mean: 29.4%), and those in patients with UC unexposed to anti-TNF- $\alpha$  treatment are 40.3% and 48% (mean: 44.15%), respectively.

and the rates of steroid-free remission in patients with UC ranged from 9%-75% (mean  $\pm$  SD: 40.7  $\pm$  33.1%, median: 38%), respectively (Figure 5). On the other hand, the rates of remission or response in CD patients ranged from 46.7%-100% (mean  $\pm$  SD: 77.5  $\pm$  27.6%, median 85.7%), and the rate of steroid-free remission in CD patients was 50%.

Regarding the efficacy of the combination therapy, Rodríguez-Lago *et al* [47] found no differences in the efficacy depending on the type of anti-TNF received during the combination therapy. They also reported that the response to the combination therapy was inversely proportional to the number of previous anti-TNF agents, but it was not influenced by the presence of primary non-response or secondary LOR. Another important aspect being considered is the regimen of CAP prescribed because an intensified regimen with longer and biweekly sessions has demonstrated rapid and higher efficacy rates without increasing the number of adverse events (AEs) [47,57]. In Table 3, it seems that the studies using a higher frequency of biweekly CAP or intensive CAP tended to demonstrate good clinical efficacy.



**Figure 4** Rates of remission or response and steroid-free remission in the combination therapies of cytopheresis and biologics in inflammatory bowel disease patients showing insufficient response or loss of response to biologics. Box plot shows that the remission rates in the combination therapies of cytopheresis and biologics range from 32%-100% (mean: 62.72%, median: 57.85%, interquartile range: 40.175%-89.275%), and the rates of steroid-free remission in the combination therapies range from 9%-75% (mean: 43%, median: 44%, interquartile range: 16.25%-68.75%).

### Safety of the combination therapy


One of the strengths of CAP is its safety profile[63]. Of note, several studies have reported the excellent safety of CAP[36,42,52,56,63]. Among these studies, Hibi *et al*[56] evaluated the safety of Adacolumn in 697 patients with UC in 53 medical institutions. They reported that no serious AEs were observed, and only mild to moderate adverse events were observed in 7.7% of patients. In addition, Motoya *et al*[52] showed that the incidence of AEs among elderly patients was similar in all patients. Regarding the safety of the combination therapy with CAP and biologics, eight out of 14 studies listed in Table 3 reported the rate of AEs[39,41,44,46-48,50,51]. Six of the eight studies reported no adverse events. On the other hand, Rodríguez-Lago *et al*[47] reported 4% (2/47) AEs related to the technique (anxiety and headache), and Tanida *et al*[50] reported 43% (3/7) AEs (one had orolabial herpes, one had a transient increase in creatinine phosphokinase due to intense physical exercise, and one had triglyceride increase). However, Tanida *et al*[50] described that AEs observed in their study were consistent with the AEs reported in the oral clinical trials for tofacitinib in ulcerative colitis induction 1 and 2 trials, suggesting that AEs observed in their study were due to AEs from tofacitinib. In summary, AEs were observed in five out of 86 patients (5.8%) in the eight studies.

Based on these results, combination therapy with CAP and biologics is safe and well-tolerated.

### Possible mechanisms of the efficacy of the combination therapy with CAP and biologics

Regarding the mechanism of the efficacy of the combination therapy of CAP and biologics, Rodríguez-Lago *et al*[47] suggested that the benefit may be related to multiple mechanisms of action. They suggested that GMA could reduce the circulating inflammatory burden in addition to direct improvement in disease activity, thus allowing the anti-TNF to restore its response. They also suggested an alternative hypothesis that states that the benefits come from the possible interaction between both treatments. This interaction could be an improvement in blood trough levels of the drug, a reduction of anti-drug antibodies, or both. In this context, several studies supported their hypothesis. Soluble TNF receptors are known to neutralize TNF without invoking a TNF-like response. Saniabadi *et al*[64] reported that blood levels of soluble TNF- $\alpha$  receptors I and II increased in IBD patients who underwent Adacolumn therapy. Hanai *et al*[65] also showed that soluble TNF- $\alpha$  receptor I/II, which are believed to have potent anti-inflammatory actions, were significantly increased in the peripheral blood at the end of the GMA session. Sono *et al*[40] showed an increase in plasma IL-10 and a decrease in circulating immune complexes and anti-nuclear antibodies during GMA therapy in GMA-responder CD patients with LOR to IFX. Furthermore, Yokoyama *et al*[43] showed that upon GMA therapy, the average plasma trough IFX increased from 0.91  $\mu\text{g/mL}$  to 1.46  $\mu\text{g/mL}$ , with concomitant decreases in C-reactive protein, IL-6, and IL-17A in IBD patients experiencing LOR to IFX. In their recent study, Yokoyama *et al*[51]





**Figure 5** Rates of remission or response and steroid-free remission in the combination therapies of cytapheresis and biologics in patients with ulcerative colitis showing insufficient response or loss of response to biologics. Box plot shows that the remission rates in the combination therapies of cytapheresis and biologics range from 32%-69% (mean: 47.97%, median: 42.9%), and the rates of steroid-free remission in the combination therapies range from 9%-75% (mean: 40.7%, median: 38%).

showed that the levels of antibodies to IFX in patients with LOR to IFX were significantly elevated compared with those indicating a sustained clinical remission. They also showed that in patients who received IFX + GMA combination therapy, the IBD symptoms significantly improved together with a decrease in antibodies to IFX. These studies suggest the possibility that GMA therapy can decrease IFX antibodies and increase plasma trough IFX in patients with LOR to IFX.

Regarding combination therapy with GMA and VDZ, it was hypothesized that this strategy might target the migration of leukocytes into the inflamed tissue by combining their mechanism of action. The peripheral inflammatory cells affected by VDZ may be removed by the ability of GMA to adsorb multiple immune cells[48]. Nakamura *et al*[49] also suggested that VDZ and GMA were able to strengthen the suppression of the migration of leukocytes into the inflamed tissue by combining their mechanisms of action. Since the migration of peripheral inflammatory cells from the blood vessels is blocked by VDZ, multiple immune cells-including the congested ones in the peripheral blood- can be removed by GMA. Thus, considering the mechanism of action of GMA and VDZ, it is suggested that this combination therapy can synergically strengthen the therapeutic effects of each therapy.

### Summary of the combination therapies with CAP and biologics

In summary, combination therapies of CAP and biologics can safely induce clinical remission or response and steroid-free remission in 32%-100% (mean: 62.72%, median: 57.85%) and 9%-75% (mean: 43%, median: 44%) of the IBD patients and in 32%-69% (mean: 47.97%, median: 42.9%) and 9%-75% (mean: 40.7%, median: 38%) of patients with UC refractory to biologics, respectively. In addition, it is a strong point of CAP that there have been no reports showing LOR to CAP during treatment. Given the excellent safety profile of CAP, these results suggest that this combination therapy can be an effective and alternative therapeutic strategy for patients with UC that experienced primary non-response or LOR to biologics. The economic burden of GMA may also be considered in decision-making[63]. A recent study showed that the availability of biosimilars had reduced the costs of anti-TNF agents, but GMA still has a cost slightly below the new biologics (*i.e.*, ustekinumab and vedolizumab) with an even better safety profile[63]. In this context, Tominaga *et al*[66] evaluated the efficacy, safety, and treatment cost of prednisolone (PSL) and GMA in 41 patients with active UC who had achieved remission with GMA or with orally administered PSL. They showed that adverse events were reported in 12.5% of the GMA group and 35.3% of the PSL group. The average medical cost was 12739.4€/patient in the GMA group and 8751.3€ in the PSL group ( $P < 0.05$ ). From these results, they concluded that the higher cost of GMA is offset by its good safety profile.

## CONCLUSION

Summarizing the results of previous studies, it is suggested that CAP has the same effectiveness for induction of remission in patients having UC with or without prior failure of thiopurines or IM. It is controversial whether CAP has a similar clinical effect in patients with UC that failed on previous biologics therapy and in biologic naïve patients. However, it seems that CAP tended to be less effective for induction of clinical remission in patients with UC that were refractory to biologics therapy. Although there was heterogeneity in the efficacy of the combination therapy with CAP and biologics in patients with IBD refractory to biologics, it is notable that combination therapies with CAP and biologics induced clinical remission or response and steroid-free remission in more than 40% of patients with UC that failed on previous biologics therapy on average. Given the excellent safety profile of CAP, it is suggested that this combination therapy can be an alternative therapeutic strategy for patients with UC that were refractory to biologics. However, the number of studies examining this combination therapy has been small and limited to date. Larger prospective studies are needed to better understand the efficacy of the combination therapy of CAP and biologics for refractory patients with UC.

## FOOTNOTES

**Author contributions:** Iizuka M was responsible for the conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version; Etou T and Sagara S was responsible for the critical revision and final approval of the final version.

**Conflict-of-interest statement:** There is no conflicts of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** Japan

**ORCID number:** Masahiro Iizuka 0000-0002-4920-2805; Takeshi Etou 0000-0001-8402-7689; Shiho Sagara 0000-0002-1900-7937.

**S-Editor:** Zhang H

**L-Editor:** A

**P-Editor:** Zhang H

## REFERENCES

- 1 Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis. *Nat Rev Dis Primers* 2020; **6**: 74 [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x]
- 2 Khan HM, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. *Clin Exp Gastroenterol* 2015; **8**: 293-302 [PMID: 26648749 DOI: 10.2147/CEG.S57248]
- 3 Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. *Lancet Gastroenterol Hepatol* 2018; **3**: 742-753 [DOI: 10.1016/S2468-1253(18)30231-0]
- 4 Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. *Gastroenterology* 2001; **121**: 255-260 [PMID: 11487534]
- 5 Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. *Aliment Pharmacol Ther* 2006; **24**: 319-330 [PMID: 16842459]
- 6 Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. *Gut* 1963; **4**: 299-315 [PMID: 14084741]
- 7 Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. *Dig Dis Sci* 1993; **38**: 1137-1146 [PMID: 8508710]
- 8 Khan N, Abbas A, Williamson A, Balart L. Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. *Dig Dis Sci* 2013; **58**: 2963-2969 [PMID: 23812861 DOI: 10.1007/s10620-013-2748-0]
- 9 Park SK, Yang SK, Ye BD, Kim KJ, Yang DH, Jung KW, Park SH, Kim JW, Byeon JS, Myung SJ, Kim JH. The long-term efficacy of azathioprine in steroid-dependent ulcerative colitis. *Scand J Gastroenterol* 2013; **48**: 1386-1393 [PMID: 24164382 DOI: 10.3109/00365521.2013.845908]
- 10 Bär F, Sina C, Fellermann K. Thiopurines in inflammatory bowel disease revisited. *World J Gastroenterol* 2013; **19**: 1699-1706 [PMID: 23555158 DOI: 10.3748/wjg.v19.i11.1699]
- 11 Jharap B, Seinen ML, de Boer NK, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJ, van Bodegraven AA.

- Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. *Inflamm Bowel Dis* 2010; **16**: 1541-1549 [PMID: [20155846](#) DOI: [10.1002/ibd.21221](#)]
- 12 **van Gennep S**, de Boer NK, D'Haens GR, Löwenberg M. Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice. *Inflamm Bowel Dis* 2017; **24**: 67-77 [PMID: [29272488](#) DOI: [10.1093/ibd/izx025](#)]
  - 13 **Ardizzone S**, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. *Gut* 2006; **55**: 47-53 [PMID: [15972298](#)]
  - 14 **Rosenberg JL**, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. *Gastroenterology* 1975; **69**: 96-99 [PMID: [1097295](#)]
  - 15 **Rutgeerts P**, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2005; **353**: 2462-2476 [PMID: [16339095](#) DOI: [10.1056/NEJMoa050516](#)]
  - 16 **Armuzzi A**, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Sociale O, Papa A, De Vitis I, Rapaccini GL, Guidi L. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. *Inflamm Bowel Dis* 2013; **19**: 1065-1072 [PMID: [23448790](#) DOI: [10.1097/MIB.0b013e3182802909](#)]
  - 17 **Sjöberg M**, Magnuson A, Björk J, Benoni C, Almer S, Friis-Liby I, Hertervig E, Olsson M, Karlén P, Eriksson A, Midhagen G, Carlson M, Lapidus A, Halfvarson J, Tysk C; Swedish Organization for the Study of Inflammatory Bowel Disease (SOIBD). Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. *Aliment Pharmacol Ther* 2013; **38**: 377-387 [PMID: [23799948](#) DOI: [10.1111/apt.12387](#)]
  - 18 **Barreiro-de Acosta M**, Lorenzo A, Mera J, Dominguez-Muñoz JE. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. *J Crohns Colitis* 2009; **3**: 271-276 [PMID: [21172286](#) DOI: [10.j.crohns](#)]
  - 19 **Mocciaro F**, Orlando A, Scimeca D, Cottone M. [Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis]. *Recenti Prog Med* 2007; **98**: 560-564 [PMID: [18044405](#)]
  - 20 **Gavalas E**, Kountouras J, Stergiopoulos C, Zavos C, Gissakis D, Nikolaidis N, Gioulema O, Chatzopoulos D, Kapetanakis N. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients. *Hepatogastroenterology* 2007; **54**: 1074-1079 [PMID: [17629042](#)]
  - 21 **Sandborn WJ**, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 2012; **142**: 257-65.e1 [PMID: [22062358](#) DOI: [10.1053/j.gastro.2011.10.032](#)]
  - 22 **Italian Group for the Study of Inflammatory Bowel Disease**, Armuzzi A, Biancone L, Daperno M, Coli A, Pugliese D, Annese V, Aratari A, Ardizzone S, Balestrieri P, Bossa F, Cappello M, Castiglione F, Cicala M, Danese S, D'Inca R, Dulbecco P, Felicangeli G, Fries W, Genise S, Gionchetti P, Gozzi S, Kohn A, Lorenzetti R, Milla M, Onali S, Orlando A, Papparella LG, Renna S, Ricci C, Rizzello F, Sostegni R, Guidi L, Papi C. Adalimumab in active ulcerative colitis: a "real-life" observational study. *Dig Liver Dis* 2013; **45**: 738-743 [PMID: [23683530](#) DOI: [10.1016/j.dld.2013.03.018](#)]
  - 23 **Sandborn WJ**, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 2014; **146**: 85-95; quiz e14 [PMID: [23735746](#) DOI: [10.1053/j.gastro.2013.05.048](#)]
  - 24 **Bosca-Watts MM**, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. *World J Gastroenterol* 2016; **22**: 10432-10439 [PMID: [28058024](#) DOI: [10.3748/wjg.v22.i47.10432](#)]
  - 25 **Tursi A**, Allegretta L, Buccianti N, Della Valle N, Elisei W, Forti G, Faggiani R, Gallina S, Hadad Y, Larussa T, Lauria A, Luzzo F, Lorenzetti R, Mocchi G, Penna A, Polimeni N, Pranzo G, Ricciardelli C, Zampalatta C, Picchio M. Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers. *J Gastrointest Liver Dis* 2017; **26**: 239-244 [PMID: [28922435](#) DOI: [10.15403/jgld.2014.1121.263.tris](#)]
  - 26 **Feagan BG**, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2013; **369**: 699-710 [PMID: [23964932](#) DOI: [10.1056/NEJMoa1215734](#)]
  - 27 **Sandborn WJ**, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med* 2017; **376**: 1723-1736 [PMID: [28467869](#) DOI: [10.1056/NEJMoa1606910](#)]
  - 28 **Ogata H**, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. *Gut* 2006; **55**: 1255-1262 [PMID: [16484504](#) DOI: [10.1136/gut.2005.081794](#)]
  - 29 **Baumgart DC**, Pintoff JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. *Am J Gastroenterol* 2006; **101**: 1048-1056 [PMID: [16573777](#)]
  - 30 **Lv R**, Qiao W, Wu Z, Wang Y, Dai S, Liu Q, Zheng X. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. *PLoS One* 2014; **9**: e86692 [PMID: [24475168](#) DOI: [10.1371/journal.pone.0086692](#)]
  - 31 **Engel T**, Ungar B, Yung DE, Ben-Horin S, Eliakim R, Kopylov U. Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. *J Crohns Colitis* 2018; **12**: 245-257 [PMID: [29077833](#) DOI: [10.1093/ecco-jcc/jjx143](#)]
  - 32 **Ben-Horin S**, Kopylov U, Chowder Y. Optimizing anti-TNF treatments in inflammatory bowel disease. *Autoimmun Rev* 2014; **13**: 24-30 [PMID: [23792214](#)]
  - 33 **Ma C**, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN. Outpatient Ulcerative Colitis Primary

- Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response. *J Clin Gastroenterol* 2015; **49**: 675-682 [PMID: [25389599](#) DOI: [10.1097/MCG.0000000000000265](#)]
- 34 **Peyrin-Biroulet L**, Danese S, Argollo M, Pouillon L, Peppas S, Gonzalez-Lorenzo M, Lytras T, Bonovas S. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2019; **17**: 838-846.e2 [PMID: [29935327](#) DOI: [10.1016/j.cgh.2018.06.026](#)]
  - 35 **Cabriada JL**, Domènech E, Ibarbroyen N, Hernández V, Clofent J, Ginard D, Gutiérrez-Ibarluzea I, Hinojosa J. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. *J Gastroenterol* 2012; **47**: 359-365 [PMID: [22105230](#) DOI: [10.1007/s00535-011-0499-2](#)]
  - 36 **Dignass A**, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B. Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. *J Crohns Colitis* 2016; **10**: 812-820 [PMID: [26818659](#) DOI: [10.1093/ecco-jcc/jjw032](#)]
  - 37 **Yamamoto T**, Iida T, Ikeya K, Kato M, Matsuura A, Tamura S, Takano R, Tani S, Osawa S, Sugimoto K, Shimoyama T, Hanai H. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. *Clin Transl Gastroenterol* 2018; **9**: 170 [PMID: [29977035](#) DOI: [10.1038/s41424-018-0037-0](#)]
  - 38 **González Carro P**, Pérez Roldán F, Roncero García Escribano O, Lafuente R, Legaz Huidobro ML, Amigo Echenagusia A. Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease. *J Clin Apher* 2006; **21**: 249-251 [PMID: [16607627](#) DOI: [10.1002/jca.20093](#)]
  - 39 **Fukunaga K**, Yokoyama Y, Kamikozuru K, Yoshida K, Kikuyama R, Nagase K, Nakamura S, Takei Y, Miwa H, Matsumoto T. Selective depletion of peripheral granulocyte/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohn's disease. *J Clin Apher* 2010; **25**: 226-228 [PMID: [20544712](#) DOI: [10.1002/jca.20242](#)]
  - 40 **Sono K**, Yamada A, Yoshimatsu Y, Takada N, Suzuki Y. Factors associated with the loss of response to infliximab in patients with Crohn's disease. *Cytokine* 2012; **59**: 410-416 [PMID: [22633084](#) DOI: [10.1016/j.cyto.2012.04.026](#)]
  - 41 **Ozeki K**, Tanida S, Mizoshita T, Tsukamoto H, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease. *Case Rep Gastroenterol* 2012; **6**: 765-771 [PMID: [23341799](#) DOI: [10.1159/000346312](#)]
  - 42 **Yokoyama Y**, Matsuoka K, Kobayashi T, Sawada K, Fujiyoshi T, Ando T, Ohnishi Y, Ishida T, Oka M, Yamada M, Nakamura T, Ino T, Numata T, Aoki H, Sakou J, Kusada M, Maekawa T, Hibi T. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice. *J Crohns Colitis* 2014; **8**: 981-991 [PMID: [24556083](#) DOI: [10.1016/j.crohns.2014.01.027](#)]
  - 43 **Yokoyama Y**, Kamikozuru K, Watanabe K, Nakamura S. Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte/monocyte apheresis: A case series. *Cytokine* 2018; **103**: 25-28 [PMID: [29291447](#) DOI: [10.1016/j.cyto.2017.12.030](#)]
  - 44 **Scrivo B**, Vitello A, Cappello M. Response to "The combination therapy with cytopheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous Anti-TNF alfa failure". *Dig Liver Dis* 2018; **50**: 1103-1104 [PMID: [29871799](#) DOI: [10.1016/j.dld.2018.05.001](#)]
  - 45 **Sáez-González E**, Aguas M, Huguet JM, Nos P, Beltrán B. Combination therapy with cytopheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF- $\alpha$  drug failure. *Dig Liver Dis* 2018; **50**: 415-417 [PMID: [29397323](#) DOI: [10.1016/j.dld.2018.01.124](#)]
  - 46 **Tanida S**, Mizoshita T, Ozeki K, Katano T, Tanaka M, Nishie H, Shimura T, Okamoto Y, Kubota E, Kataoka H, Joh T. Combination Therapy With Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Ustekinumab in Patients With Refractory Crohn's Disease. *Ther Apher Dial* 2018; **22**: 295-300 [PMID: [29790276](#) DOI: [10.1111/1744-9987.12697](#)]
  - 47 **Rodríguez-Lago I**, Sempere L, Gutiérrez A, Núñez A, Leo Carnerero E, Hinojosa E, Mora M, Cañete F, Mañosa M, Herrera C, Beltrán B, Forés A, Arjona D, Barreiro-de Acosta M, Khorrami S, Aguirre U, Ginard D, Cabriada JL. Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. *Scand J Gastroenterol* 2019; **54**: 459-464 [PMID: [30982369](#) DOI: [10.1080/00365521.2019.1600715](#)]
  - 48 **Rodríguez-Lago I**, Benítez JM, Sempere L, Sáez-González E, Barreiro-de Acosta M, de Zárate JO, Cabriada JL. The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis? *J Clin Apher* 2019; **34**: 680-685 [PMID: [31518013](#) DOI: [10.1002/jca.21746](#)]
  - 49 **Nakamura M**, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Ohashi A, Kajikawa G, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Fujishiro M. Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis. *Intern Med* 2020; **59**: 3009-3014 [PMID: [32727993](#) DOI: [10.2169/internalmedicine.5302-20](#)]
  - 50 **Tanida S**, Ozeki K, Mizoshita T, Kitagawa M, Ozeki T, Tanaka M, Nishie H, Shimura T, Kubota E, Kataoka H. Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis. *J Clin Med Res* 2020; **12**: 36-40 [PMID: [32010420](#) DOI: [10.14740/jocmr4037](#)]
  - 51 **Yokoyama Y**, Sawada K, Aoyama N, Yoshimura N, Sako M, Hirai F, Kashiwagi N, Suzuki Y. Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients With Inflammatory Bowel Disease Showing Lost Response to Infliximab. *J Crohns Colitis* 2020; **14**: 1264-1273 [PMID: [32166331](#) DOI: [10.1093/ecco-jcc/jjaa051](#)]
  - 52 **Motoya S**, Tanaka H, Shibuya T, Osada T, Yamamoto T, Hongo H, Mizuno C, Saito D, Aoyama N, Kobayashi T, Ito H, Tanida S, Nojima M, Kokuma S, Hosoi E. Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study. *BMC Gastroenterol* 2019; **19**: 196 [PMID: [31752695](#) DOI: [10.1186/s12876-019-1110-1](#)]
  - 53 **Yamamoto T**, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. *Inflamm Bowel Dis* 2010; **16**: 1905-1911 [PMID: [20310015](#) DOI: [10.1002/ibd.21260](#)]



- 54 **Lindberg A**, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. *BMC Gastroenterol* 2010; **10**: 73 [PMID: 20604939 DOI: 10.1186/1471-230X-10-73]
- 55 **Sandborn WJ**. Preliminary data on the use of apheresis in inflammatory bowel disease. *Inflamm Bowel Dis* 2006; **12** Suppl 1: S15-S21 [PMID: 16378006]
- 56 **Hibi T**, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. *Dig Liver Dis* 2009; **41**: 570-577 [PMID: 19211314 DOI: 10.1016/j.dld] ]
- 57 **Sakuraba A**, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. *Am J Gastroenterol* 2009; **104**: 2990-2995 [PMID: 19724269 DOI: 10.1038/ajg.2009.453]
- 58 **Takayama T**, Kanai T, Matsuoka K, Okamoto S, Sujino T, Mikami Y, Hisamatsu T, Yajima T, Iwao Y, Ogata H, Hibi T. Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. *J Crohns Colitis* 2013; **7**: e49-e54 [PMID: 22633997 DOI: 10.1016/j.crohns.2012.05.005]
- 59 **Iizuka M**, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. *World J Gastroenterol* 2021; **27**: 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194]
- 60 **Cabriada JL**, Ibagoyen N, Hernández A, Bernal A, Castiella A. Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year. *Dig Liver Dis* 2010; **42**: 432-435 [PMID: 19833566 DOI: 10.1016/j.dld.2009.09.001]
- 61 **Imperiali G**, Amato A, Terpin MM, Beverina I, Bortoli A, Devani M, Viganò C; Study Group on IBD (GSMII). Granulocyte-Monocyte Apheresis in Steroid-Dependent, Azathioprine-Intolerant/Resistant Moderate Ulcerative Colitis: A Prospective Multicenter Study. *Gastroenterol Res Pract* 2017; **2017**: 9728324 [PMID: 29403531 DOI: 10.1155/2017/9728324]
- 62 **Ishiguro Y**, Ohmori T, Umemura K, Iizuka M. Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: A multicenter cohort study. *Ther Apher Dial* 2021; **25**: 502-512 [PMID: 33029920 DOI: 10.1111/1744-9987.13594]
- 63 **Domènech E**, Grífols JR, Akbar A, Dignass AU. Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective. *World J Gastroenterol* 2021; **27**: 908-918 [PMID: 33776362 DOI: 10.3748/wjg.v27.i10.908]
- 64 **Saniabadi AR**, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M, Beretta A, Bjarnason I, Lofberg R. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? *J Clin Apher* 2005; **20**: 171-184 [PMID: 15892107 DOI: 10.1002/jca.20046]
- 65 **Hanai H**, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Saniabadi A. Correlation of serum soluble TNF- $\alpha$  receptors I and II levels with disease activity in patients with ulcerative colitis. *Am J Gastroenterol* 2004; **99**: 1532-1538 [PMID: 15307873 DOI: 10.1111/j.1572-0241.2004.30432.x]
- 66 **Tominaga K**, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. *BMC Gastroenterol* 2013; **13**: 41 [PMID: 23452668 DOI: 10.1186/1471-230X-13-41]





Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

